This is due to the spatiotemporal release of the BRD4 inhibitor JQ1 from ELJNV in a laser-light-controlled manner, which simultaneously causes antitumor immunity and blocks the PD-L1/PD-1 checkpoint to prevent tumor recurrence and metastasis. This evidence concerns the gene CD274 and neoplasm.